WallStSmart

Boston Scientific Corp (BSX)vsNeuronetics Inc (STIM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 13358% more annual revenue ($20.07B vs $149.16M). BSX leads profitability with a 14.4% profit margin vs -26.2%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

STIM

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for STIM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

STIM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
85.7%10/10

Revenue surging 85.7% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

STIM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$100.45M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-134.9%2/10

ROE of -134.9% — below average capital efficiency

Profit MarginProfitability
-26.2%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : STIM

The strongest argument for STIM centers on Revenue Growth. Revenue growth of 85.7% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : STIM

The primary concerns for STIM are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while STIM is a hypergrowth play — different risk/reward profiles.

STIM carries more volatility with a beta of 0.94 — expect wider price swings.

STIM is growing revenue faster at 85.7% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 38/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Neuronetics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.

Want to dig deeper into these stocks?